CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
markets
Market Minute: Reporting Season, Part 1
stocks
ASX reporting season wrap: BHP, banks, CSL bloodbath and more
stocks
Stock showdown: How do ASX healthcare giants compare on key investing criteria?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,234.30 | 55.70 | -0.60% |
CAC 40 | 7,969.69 | 31.40 | 0.40% |
DAX 40 | 24,363.09 | 69.75 | 0.29% |
Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,339.14 | 234.53 | 0.93% |
NASDAQ | 21,496.54 | 396.22 | 1.88% |
Nikkei 225 | 42,633.29 | 23.12 | 0.05% |
NZX 50 Index | 13,042.76 | 151.31 | -1.15% |
S&P 500 | 6,466.91 | 96.74 | 1.52% |
S&P/ASX 200 | 8,967.40 | 57.00 | -0.63% |
SSE Composite Index | 3,825.76 | 54.66 | 1.45% |